To the Editor.—
The appearance of deposits of triamterene in kidney stones is now widely recognized (1980; 244:2443 and 1981;245:2494).1-4 We previously reported2 that 0.4% of all kidney stones analyzed showed some deposits of this drug. We estimated the annual incidence of triamterenecontaining stones to be 1/2,000 users of a mixture of triamterene and hydrochlorothiazide (Dyazide).3We have done an epidemiologic study to define the risk of kidney stones better in patients exposed to triamterene. We compared 799 patients attending the Kaiser-Permanente Medical Center clinics, San Francisco, who had regularly used Dyazide, with age- and sex-matched control subjects of two types. One group had used hydrochlorothiazide regularly, and the other group received no diuretic therapy. Patients with a history of kidney stones were excluded. The mean duration of follow-up was almost five years, and the mean dosage of Dyazide was one capsule a day, with 17% of
Ettinger B. Risk of Kidney Stones. JAMA. 1982;248(16):1971. doi:10.1001/jama.1982.03330160023005
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: